palmidrol has been researched along with Osteoarthritis in 5 studies
palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection
palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.
Osteoarthritis: A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.
| Excerpt | Relevance | Reference |
|---|---|---|
| ", PEA co-ultramicronized with the natural antioxidant quercetin (PEA-Q), administered orally in two different rat models of inflammatory and OA pain, namely carrageenan paw oedema and sodium monoiodoacetate (MIA)-induced OA." | 7.85 | A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models. ( Britti, D; Crupi, R; Cuzzocrea, S; Di Paola, R; Evangelista, M; Fusco, R; Gugliandolo, E; Impellizzeri, D; Morittu, VM; Schievano, C, 2017) |
| "To carry out a randomized clinical trial to compare the effect of palmitoylethanolamide (PEA) versus ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), for pain relief in temporomandibular joint (TMJ) osteoarthritis or arthralgia." | 5.16 | Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. ( Bartolucci, ML; Bonetti, GA; Bortolotti, F; Gatto, MR; Marini, I, 2012) |
| ", PEA co-ultramicronized with the natural antioxidant quercetin (PEA-Q), administered orally in two different rat models of inflammatory and OA pain, namely carrageenan paw oedema and sodium monoiodoacetate (MIA)-induced OA." | 3.85 | A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models. ( Britti, D; Crupi, R; Cuzzocrea, S; Di Paola, R; Evangelista, M; Fusco, R; Gugliandolo, E; Impellizzeri, D; Morittu, VM; Schievano, C, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jung, JI | 1 |
| Lee, HS | 1 |
| Jeon, YE | 1 |
| Kim, SM | 1 |
| Hong, SH | 1 |
| Moon, JM | 1 |
| Lim, CY | 1 |
| Kim, YH | 1 |
| Kim, EJ | 1 |
| Britti, D | 1 |
| Crupi, R | 1 |
| Impellizzeri, D | 1 |
| Gugliandolo, E | 1 |
| Fusco, R | 1 |
| Schievano, C | 1 |
| Morittu, VM | 1 |
| Evangelista, M | 1 |
| Di Paola, R | 1 |
| Cuzzocrea, S | 1 |
| Alsalem, M | 1 |
| Haddad, M | 1 |
| Aldossary, SA | 1 |
| Kalbouneh, H | 1 |
| Altarifi, A | 1 |
| Jaffal, SM | 1 |
| Abbas, MA | 1 |
| Aldaoud, N | 1 |
| El-Salem, K | 1 |
| Zhou, P | 1 |
| Xiang, L | 1 |
| Yang, Y | 1 |
| Wu, Y | 1 |
| Hu, T | 1 |
| Liu, X | 1 |
| Lin, F | 1 |
| Xiu, Y | 1 |
| Wu, K | 1 |
| Lu, C | 1 |
| Ren, J | 1 |
| Qiu, Y | 1 |
| Li, Y | 1 |
| Marini, I | 1 |
| Bartolucci, ML | 1 |
| Bortolotti, F | 1 |
| Gatto, MR | 1 |
| Bonetti, GA | 1 |
1 trial available for palmidrol and Osteoarthritis
| Article | Year |
|---|---|
Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain.
Topics: Adult; Amides; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Double-Blind Method; Endocannabi | 2012 |
4 other studies available for palmidrol and Osteoarthritis
| Article | Year |
|---|---|
Anti-inflammatory activity of palmitoylethanolamide ameliorates osteoarthritis induced by monosodium iodoacetate in Sprague-Dawley rats.
Topics: Administration, Oral; Amides; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Dose-Respo | 2021 |
A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models.
Topics: Administration, Oral; Amides; Animals; Anti-Inflammatory Agents; Carrageenan; Drug Combinations; Ede | 2017 |
Role of cannabinoid receptor 1 and the peroxisome proliferator-activated receptor α in mediating anti-nociceptive effects of synthetic cannabinoids and a cannabinoid-like compound.
Topics: Amides; Analgesics; Animals; Cannabinoids; Dronabinol; Ethanolamines; Iodoacetic Acid; Male; Motor A | 2019 |
N-Acylethanolamine acid amidase (NAAA) inhibitor F215 as a novel therapeutic agent for osteoarthritis.
Topics: Amides; Amidohydrolases; Animals; Anti-Inflammatory Agents; Cartilage; Cells, Cultured; Chondrocytes | 2019 |